Company intelligence / Profile preview

Invenshure

Minneapolis, Minnesota, United Statesinvenshure.com ↗

Ownership: Private
Employees: ~36
Development stage: Other

Overview

Invenshure does not conduct clinical trials itself but launches and accelerates biotech startups. For example, its spinout MEKanistic Therapeutics has shown preclinical efficacy with reduced toxicity in tumor models and aims for IND approval with Phase 1 trials anticipated soon. No direct clinical results attributable to the parent entity.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Investors

Drug pipeline

1 asset

MTX-531

Pre-clinical

Indications: Head and neck cancer

Partnerships

Leading scientists/institutionsImbio/Flywheel Exchange (under Invenshure umbrella)

Beyond the preview

Go deeper on Invenshure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invenshure.

Explore the full profile